







eMeasure Title	NQF Number	CMS ID
A Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	NQF0068	CMS164v4
B Controlling High Blood Pressure	NQF0018	CMS165v4
C Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	Pending	CMS347v0
S Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	NQF0028	CMS138v4

·	


Many Clinics did not Know If Their EHR Could Pull ABCS

How Does the PF Guide?

CQMs Part of HiTech Act

- · Certification of EHR's
- EHR's required min 9 Certified CQM's
- Designed for Quality Payment Programs
- Standardized Specifications
- Updated Annually
- QPP, MU, PQRS, HEDIS, ACO etc....
- Evidence Based





Measure	Measure Number	Measure Description
Aspirin When Appropriate	NQF 0068	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic Percentage of patients aged 18 years and older with IVD with documented use of aspirin or other antithrombotic (78-80% in 2015)
Blood Pressure Control	NQF 0018	Hypertension (HTN): Controlling High Blood Pressure Percentage of patients aged 18 through 85 years who had a diagnosis of HTN and whose blood pressure was adequately controlled (<140/90) during the measurement year (64-71% in 2015)
Cholesterol Management	PQRS 438	Statis Therapy for Prevention and Treatment of Cardiovascular Disease Percentage of the following patients who were prescribed or were on statin therapy during the measurement period. I disposed with or currently have an active disposite of clinical attreocement of the Adults ageds 2:1 years who were previously disposed with or currently have an active disposite of clinical attreocement of the Adults ageds 2:1 years with a tasting or direct low-density lipoprotein cholestered (ID-C) evels 1:9 mg/dL-C) Adults aged 4:0.73 years with a diagnosis of clabetes with a tasting or direct LID-C level 0:73 htm mg/dL-C).
Smoking Cessation	NQF 0028	Preventive Care and Screening: Tobacco Use Percentage of patients aged 18 years and older who were screened about tobacco use one or more times within 24 months and who received cessation counseling intervention if identified as a tobacco user (83-91% in 2015)


What we did

CHPL	. Website
Certified Health IT Product List	Senit BFLQ DIS Blanter Corport Frederic DFL Rousser
Q. Hilistore previous starch	=Browse all
API Info for 2015 Ed. Products	SED Info for 2015 Ed. Products
Products: Corrective Action	Decertified Products
Inactive Certificates	Banned Developers



		-						
Ce	rtified Healt	h IT Product	List		Search CHPL Q. ONS 10 Creature	Compare Products»	CHPL Resources+	Shorte
2014	eClinicaWorks, LLC	eClinicalWorks	V10	Jul 31, 2014	CHP-023392	٥	Details +Compa	+Cert
2014	eClinicalWorks, LLC	eClinicalWorks	V10	Jul 31, 2014	CHP-023393	٥	-Details +Compa	+Cert
2014	eClinicalWorks, LLC	eClinicalWorks	V10	Jul 31, 2014	CHP-023394	٥	-Details +Comps	+Cert
2014	eClinicalWorks, LLC	eClinicalWorks	V10 SP2	May 26, 2017	14.04.04.2883.eCil.10.01.1.17052	6 0	-Details +Compa	+Cert
2015	eClinicaWorks, LLC	eClinicalWorks	V11	Dec 28, 2017	15.04.04.2883.eCii.11.00.1.17122	8 0	Details + Compa	+Cert








Template - Dashboard for Ev	idenceNOW ABCS Measu	res (insert rep	orting period]				
Practice: [insert prectice nome] EvidenceNOW AI	State: WASHINGTON	Cooperati Your Practice's Performance ¹	Vo: Healthy Hea Your Cooperative's Practices' Performance	rts Northwest (H State Average Performance ²	2N) National Baseline for Million Hearts ³	Million Hearts Clinical Target ⁴	AHRQ EvidenceNOW Clinical Target
ASPURIN Percentage of patients 18 years of agg aline for action myocardial infraction (graft (CABG) or percutaneous contrast roothe prior to the measurement pee degnoiss of isherive vascular disease period, and who had documentation o auththrombiotic durate the measurement	4M(), coronary artery bypass y interventions (PCI) in the 12 iod, or who had an active (IND) during the measurement of use of aspirin or another	81%	[XX%]	74%	54%	70%	80%
BLOOD PRESSURE CONTROL Percentage of patients 18-85 years of hypertension and whose blood press (<140/90mmHg) during the measurem (018)	age who had a diagnosis of re was adequately controlled	61%	[XX%]	64%	53%	70%	80%
Cholesterect. MANAGEMENt [®] Percentage of high-risk adult parameter previously diagnosed with or currently clinical athereosel erotic card orwarcular patients aged 3–923 years with a failul Lipporteam. Cholesterel (LLE-C) lineel 40-75 years with a diagnosis of diabet level of 70-189 mg/g), who were press residuation thereing ukung the measu	have an active diagnosis of disease (ASCVD); OR adult g or direct Low-Density = 190 mg/dj; OR patients aged es with a fasting or sircet LDL-C onked or are already on statin	42%	[XX%]	[Data not available]	32%	70%	80%
SMOKING CESSATION Percentage of patients aged 18 years tobacco use one or more times within cessation counseling intervention if id 256/NGP 00281	and older who were screened for 24 months AND who received	55%	[XX%]	83%	22%	70%	80%




Now we Have a Measure Validate "Make it Real"


Importension Guidelines Importension (BAC) (15.9% yrs) ALL 446, 31 36 68 11 Cardia:	Satisfact Satisfact Not on N
Viguan Name 3 Measure Name Image: Statistical Statis	Measure Name Satisfact on Not on Not provider Not provider Not provider Total provider <thtotal provider <thtotal provider</thtotal </thtotal
Viguan Name 3 Measure Name Image: Statistical Statis	Measure Name Satisfact on Not on Not provider Not provider Not provider Total provider <thtotal provider <thtotal provider</thtotal </thtotal
Program Name ™ Statistical stati	memory production
Program Name ™ Statistical stati	memory production
Program Name ™ Statistical stati	m m stratified Provide Transmission Stratified Transmission Stratifi
on Statistical Provide Program Name Statistical Provide Provide Program Name	m m stratified Provide Transmission Stratified Transmission Stratifi
Program Name ™ Statistical stati	m m stratified Provide Transmission Stratified Transmission Stratifi
Provider	Measure Name Provider Name 37 Provider Factor Provider Fac
Program me ™ Measure Name ™ Measure	Thesawer Name ▼ Total <thtotal< th=""> Total <thtotal< th=""></thtotal<></thtotal<>
Importension Guidelines Importension (BAC) (15.9% yrs) ALL 446, 31 36 68 11 Cardia:	Bigstemation Bigstemation<
Cardiac Care quadelines Biod Pressure Control In CA (14A)(9) AL 6% 17 8 36 11 Currical care quadelines Biod Pressure Control In CM (14A)(9) ALI 9% 13 6 10 Currica care quadelines Biod Pressure Control In CM (14A)(9) ALI 9% 23 8 10 Currica care quadelines Biod Pressure Control In CM (14A)(9) ALI 9% 23 8 0 Currica care quadelines Biod Pressure Control In CM (14A)(9) ALI 9% 23 8 0 Cardiac Care quadelines Biod Pressure Control In CM (14A)(9) ALI 49% 22 88 112 21 Cardiac Care quadelines Duble test screening (n CAD (14 th thing)) ALI 42% 12 22 0 0 Cardiac Care quadelines Duble test screening (n CAD (14 th thing)) ALI 135 4 22 28 0 0 Cardiac Care quadelines Cardiac Care quadelines Cardiac Care quadelines 24 28 0 0 <t< th=""><th>Biodof Pressure Control in CAD (140/90) ALL 65% 17 8 36 11 11/1/202 6s Biodof Pressure Control in CPI (140/90) ALL 97% 15 4 15 0 11/1/202 8s Biodof Pressure Control in CPI (140/90) ALL 95% 15 4 15 0 11/1/202 8s Biodof Pressure Control in CPI (140/90) ALL 95% 25 16 38 0 11/1/202 8s Biodof Pressure Screeming in CAD ALL 95% 25 1 28 0 11/1/202 Solbader Screeming in CAD ALL 42% 72 88 172 11/1/1/202</th></t<>	Biodof Pressure Control in CAD (140/90) ALL 65% 17 8 36 11 11/1/202 6s Biodof Pressure Control in CPI (140/90) ALL 97% 15 4 15 0 11/1/202 8s Biodof Pressure Control in CPI (140/90) ALL 95% 15 4 15 0 11/1/202 8s Biodof Pressure Control in CPI (140/90) ALL 95% 25 16 38 0 11/1/202 8s Biodof Pressure Screeming in CAD ALL 95% 25 1 28 0 11/1/202 Solbader Screeming in CAD ALL 42% 72 88 172 11/1/1/202
Cardia:	ss Blood Pressure Control In (VF 144/99) ALL 79% 1.5 4 1.9 0.11/10/201 ss Blood Pressure Control In VD 14/49/00 ALL 96% 22 1.6 88 0.11/10/201 ss Blood Pressure Screening in CAD ALL 96% 25 1 26 0.11/10/201 ss Blood Pressure Screening for challents on statin therapy ALL 49% 25 1 26 0.11/10/201 ss Blood Pressure Screening for patients on statin therapy ALL 49% 27 28 172 12/11/10/201
Cardia: Care Guidelines Blood Pressure Control In 10/ 104/90) ALL Str 22 18 38 0 Cardia: Care Guidelines Blood Pressure Screening in CAD ALL 965 25 1 26 0 Cardia: Care Guidelines Blood Pressure Screening in CAD ALL 475 72 88 172 21 Cardia: Care Guidelines Lipde Control in CAD (Less thin 100) ALL 135 4 22 26 0 1 Cardia: Care Guidelines Lipdd Forces in CAD (Less thin 100) ALL 135 4 22 26 0 1 Cardia: Care Guidelines Lipdd Forces in CAD (Less thin 100) ALL 135 4 22 26 0 1 Cardia: Care Guidelines Lipdd Forces in CAD (Less thin 20) ALL 135 9 17 26 0 26 1 1 Cardia: Care Guidelines CAD ALL 956 25 0 26 1 1	ss Blood Pressure Control in IVD (140/90) ALL 58% 22 16 38 0 11/10/20 ss Blood Pressure Streening in CAD ALL 96% 25 1 26 0 11/10/20 ss Blood Pressure Streening for CAB US ALL 96% 25 1 26 0 11/10/20 ss Diabetes streening for patients on statin threngy ALL 42% 72 88 172 121 11/10/20
Cardial-Care Guidelines Biodo Pressure Screening In CAD ALL 996 25 1 26 0 Cardial-Care Guidelines Dabetes screening (for galantist on staft thrange) ALL 426 72 88 122 0 Cardial-Care Guidelines Lipid Control in CAD (Less thin 100) ALL 15% 4 22 26 0 Cardial-Care Guidelines Lipid Process on CAD (Less thin 100) ALL 35% 9 17 26 0 Cardial-Care Guidelines Lipid Process on CAD (Less thin 100) ALL 35% 9 17 26 0 Cardial-Care Guidelines Lipid Process on CAD (Less thin 100) ALL 95% 25 0 26 1	es Blood Pressure Screening in CAD ALL 96% 25 1 26 0 11/10/20. es Diabetes screening for patients on statin therapy ALL 42% 72 88 172 12 11/10/20.
Cardial-Care Guidelines Dubbers strenening for patients on startin therapy ALL 42% 72 88 127 121 Cardial-Care Guidelines Upid Control in CAD (Less thun 100) ALL 15% 4 22 26 01 Cardial-Care Guidelines Upid Control in CAD (Less thun 100) ALL 13% 9 17 26 01 Cardial-Care Guidelines Upid Process in CAD (Lay see/) ALL 13% 9 17 26 01 Cardial-Care Guidelines Lipid Process in CAD (Lay see/) ALL 13% 9 17 26 01 Cardial-Care Guidelines Lipid Process in CAD (Lay see/) ALL 13% 9 12 0 Cardial-Care Guidelines CAD ALL 95% 20 0 1	es Diabetes screening for patients on statin therapy ALL 42% 72 88 172 12 11/10/20
Candiac Care Guidelines Lopid Control in CAD (Less than 100) ALL 15% 4 22 36 0 Candiac Care Guidelines Lupid Control in CAD (Less than 100) ALL 35% 9 17 26 0 Candiac Care Guidelines Lupid Yoos Care CAD (Lay sea) ALL 35% 9 17 26 0 Candiac Care Guidelines Lupid Yoos Care Care Care Care Care Care Care Care	
Cardiac Care Guidelines Lipid Process in CAD (1x year) ALL 35% 9 17 26 01 Use of aspirin or another anti-atherosclerotic in Cardiac Care Guidelines ALL 96% 25 0 26 1 1	
Use of aspirin or another anti-atherosclerotic in Cardiac Care Guidelines CAD ALL 96% 25 0 26 1 1	
Cardiac Care Guidelines CAD ALL 96% 25 0 26 1 1	
Hypertension: Diabetes or chronic kidney disease	Hypertension: Diabetes or chronic kidney disease
Hypertension Guidelines BP control 140/90 ALL 51% 32 31 63 0 1	nes BP control 140/90 ALL 51% 32 31 63 0 11/10/201









Now that We know Patient Care Gaps QI Begins!




















Example: Improving Controlling High Blood Pressure Measure


- 1. Ran EHR Canned Report for Controlling High Blood Pressure CMS 165
- 2. Validated Measure -Looked up 10 pts
- 3. Team set goals (AIM Statement)
- 4. PDSA Cycle Process determined
- 5. Tested small changes
- 6. Adopted Improvements
















Why Practice Facilitation is Important

Help to providers, especially smaller clinics, to:

#1 Be able to use EHRs to generate data reports

#2 Look at the data and identify care gaps

#3 Develop processes for improving care and outcomes

#4 Report data on a regular basis

#5 Understand what is coming down the pike, and the need to change in order to survive

